Curcuma longa aqueous extract: A potential solution for the prevention of corneal scarring as a result of pterygium surgical excision (Review)

Stati, Gianmarco; Sancilio, Silvia; Basile, Mariangela; Angelini, Antonio; Pietro, Roberta Di

doi:10.3892/ijmm.2020.4738

Cited by 4 publications

(2 citation statements)

References 80 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tolerate up to a dose of 8000 mg per day. (Dorota et al, 2019;Stati et al, 2020) Curcumin belongs to the group of natural antioxidants. The effect of curcumin on free radicals is carried out by several different mechanisms.…”

Section: Therapymentioning

confidence: 99%

Curcumin as Potential Adjuvant Therapy to Prevent Recurrence in Pterygium Excision.

Abdurrauf¹,

Ramadhan²,

Nurwasis³

et al. 2022

IJRP

View full text Add to dashboard Cite

Pterygium is a wing-shaped growth from the conjunctiva and fibrovascular tissue onto the surface of the cornea. It has a high postoperative recurrence rate (which can be as high as 89% and its severity may vary according to the approach adopted and the preoperative conditions). To reduce the postoperative recurrence rate, several surgical techniques have been developed. The pathophysiology of pterygium development is diverse, one of the main factors is the proliferative process initiated by the TGF-mediator. One of the therapies developed to prevent pterygium recurrence is by targeting therapy on the proliferative pathway by adding pterygium surgery with adjuvant MMC therapy. MMC plays a role in inhibiting DNA synthesis, thereby reducing TGF-expression and ultimately inhibiting cell proliferation. Although it can reduce the recurrence rate quite well, MMC has numbers of complications. Therefore, an agent is needed to suppress pterygium proliferation which is relatively safer. Curcumin is a compound derived from the tuber of Curcuma longa L. which includes polyphenols. Curcumin modulates proliferation by stimulating the formation of TGIF which is a negative regulator of TGF-so that it can modulate proliferation.

show abstract

Section: Therapymentioning

confidence: 99%

Curcumin as Potential Adjuvant Therapy to Prevent Recurrence in Pterygium Excision.

Abdurrauf¹,

Ramadhan²,

Nurwasis³

et al. 2022

IJRP

View full text Add to dashboard Cite

show abstract

“…These treatments have not led to a consistent reduction in the relapse cases. Several research groups reported a different percentage of relapses, corneal scarring and side effects respectively, due to surgical procedure and drugs utilized [ 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Development and Characterization of Curcumin-Silver Nanoparticles as a Promising Formulation to Test on Human Pterygium-Derived Keratinocytes

et al. 2022

Self Cite

View full text Add to dashboard Cite

Pterygium is a progressive disease of the human eye arising from sub-conjunctival tissue and extending onto the cornea. Due to its invasive growth, pterygium can reach the pupil compromising visual function. Currently available medical treatments have limited success in suppressing efficiently the disease. Previous studies have demonstrated that curcumin, polyphenol isolated from the rhizome of Curcuma longa, induces apoptosis of human pterygium fibroblasts in a dose- and time-dependent manner showing promising activity in the treatment of this ophthalmic disease. However, this molecule is not very soluble in water in either neutral or acidic pH and is only slightly more soluble in alkaline conditions, while its dissolving in organic solvents drastically reduces its potential use for biomedical applications. A nanoformulation of curcumin stabilized silver nanoparticles (Cur-AgNPs) seems an effective strategy to increase the bioavailability of curcumin without inducing toxic effects. In fact, silver nitrates have been used safely for the treatment of many ophthalmic conditions and diseases for a long time and the concentration of AgNPs in this formulation is quite low. The synthesis of this new compound was achieved through a modified Bettini’s method adapted to improve the quality of the product intended for human use. Indeed, the pH of the reaction was changed to 9, the temperature of the reaction was increased from 90 °C to 100 °C and after the synthesis the Cur-AgNPs were dispersed in Borax buffer using a dialysis step to improve the biocompatibility of the formulation. This new compound will be able to deliver both components (curcumin and silver) at the same time to the affected tissue, representing an alternative and a more sophisticated strategy for the treatment of human pterygium. Further in vitro and in vivo assays will be required to validate this formulation.

show abstract

The gelatin sponge loaded with curcumin coating exhibits a synergistic effect of hemostasis, anti-inflammatory, and anti-scarring

Tan,

Xi,

Xue

et al. 2025

Biomaterials Advances

View full text Add to dashboard Cite

Curcuma longa aqueous extract: A potential solution for the prevention of corneal scarring as a result of pterygium surgical excision (Review)

Cited by 4 publications

References 80 publications

Curcumin as Potential Adjuvant Therapy to Prevent Recurrence in Pterygium Excision.

Curcumin as Potential Adjuvant Therapy to Prevent Recurrence in Pterygium Excision.

Development and Characterization of Curcumin-Silver Nanoparticles as a Promising Formulation to Test on Human Pterygium-Derived Keratinocytes

The gelatin sponge loaded with curcumin coating exhibits a synergistic effect of hemostasis, anti-inflammatory, and anti-scarring

Contact Info

Product

Resources

About